SINTX Technologies Inc
sintx.comSINTX Technologies Inc (NASDAQ: SINT) is a biomaterials and medical device company that designs, manufactures, and sells silicon nitride (SiN) ceramic products for spinal fusion, joint replacement, and antipathogenic applications. Revenue comes from direct product sales of silicon nitride implants and advanced ceramic powders, supplemented by consulting, product development, and royalty arrangements with surgeons and healthcare professionals. The company operates a 30,764 square foot corporate facility in Salt Lake City, Utah, which includes 19,000 square feet of FDA-registered, ISO 13485:2016 certified, and AS9100D certified manufacturing space. Products are primarily sold in the United States. SINTX has manufactured silicon nitride spinal implants for over 10 years and is pursuing expanded applications in foot and ankle, dental, maxillofacial, and arthroplasty markets, as well as antipathogenic products incorporating silicon nitride powder. The company has received three NIH grants to develop 3D printed silicon nitride and polymer implantable medical devices. Financing activity in FY2025 provided $8.2 million, primarily from warrant exercises and ATM common stock issuances, indicating reliance on equity markets rather than operating cash flow.
Products & Services
Silicon nitride (SiN) spinal fusion implants; silicon nitride and PEEK composite implants designed for 3D printing and patient-specific applications; advanced ceramic powders; antipathogenic silicon nitride powder for incorporation into face masks, drapes, filters, sutures, and wound care devices; porous and textured silicon nitride implants.
Revenue Model
Transactional product sales of silicon nitride implants and advanced ceramic powders; royalty and consulting arrangements with surgeons and healthcare professionals; OEM and private label manufacturing partnerships pursued but not yet disclosed as a material revenue stream in the FY2025 filing.
Customers & Markets
Surgeons and hospitals in the spinal fusion and joint replacement markets; medical OEM and private label partners; end markets include spinal fusion, arthroplasty, foot and ankle, dental, and maxillofacial; antipathogenic applications targeting infection-control and wound care device manufacturers.
Geographic Exposure
Primarily United States; international sales subject to country-specific regulatory requirements including EU MDR CE marking; ANVISA RDC 665 compliance indicates Brazilian market activity.
Financial Snapshot
Loading...
